A carregar...
Gefitinib or erlotinib in previously treated non–small‐cell lung cancer patients: a cohort study in Taiwan
Among treatment modalities for lung cancer, the most promising therapy is the use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs). Both erlotinib and gefitinib, the two first‐generation EGFR‐TKIs, exhibit significant clinical responses for patients with lung adenocarcinoma...
Na minha lista:
| Publicado no: | Cancer Med |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5504326/ https://ncbi.nlm.nih.gov/pubmed/28639751 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1121 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|